Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Izencitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 known ✓ | P29597 | 20/20 | 1.00 |
| ▸ | JAK3 known ✓ | P52333 | 19/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 14/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 12/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.65 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Izencitinib SCHEMBL21229638 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL18260452 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL29509287 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL29376813 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL18269687 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL24594552 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL18260453 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL21574323 | 1.00 | TYK2 (1.00) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL18260577 | 0.97 | TYK2 (0.94) | TYK2JAK3JAK1JAK2P2RX3 | |
| Izencitinib SCHEMBL18260576 | 0.97 | TYK2 (0.94) | TYK2JAK3JAK1JAK2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3569604-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-07-06 | — | — | EP | disclosed |